Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Analysts
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the […]
